Strategic Focus Target antimicrobial resistance and immuno-oncology spaces with Bugworks’ novel broad-spectrum antibiotics and differentiated assets to secure partnerships or licensing deals with larger pharma players seeking early access to innovative antibacterials.

R&D Funding Momentum Leverage the $18M Series B1 funding and recent investor interest to position for co-development or f underwritten clinical programs with strategic investors, CROs, or biopharma collaborators aiming to accelerate AMR candidates.

Clinical & IP Positioning Highlight the unique class of broad-spectrum antibiotics as defensible intellectual property with potential for fast-tracked studies; pursue out-licensing or milestone-based collaborations with larger biopharma seeking differentiated antimicrobial portfolios.

Market Readiness Capitalize on increasing focus on combating drug-resistant infections by engaging public health and government-funded programs for joint development, grant-backed trials, or public-private partnerships to de-risk early-stage development.

Strategic Alliances Proactively approach mid- to large-cap biotech and specialty pharma with complementary oncology or infectious disease portfolios, offering Bugworks’ assets for co-development, joint ventures, or regional manufacturing partnerships to expand reach.